Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · IEX Real-Time Price · USD
11.32
+0.22 (1.98%)
At close: May 17, 2024, 4:00 PM
11.86
+0.54 (4.77%)
After-hours: May 17, 2024, 6:43 PM EDT
MRVI Revenue
Maravai LifeSciences Holdings had revenue of $274.10M in the twelve months ending March 31, 2024, down -61.81% year-over-year. Revenue in the quarter ending March 31, 2024 was $64.18M, a -18.79% decrease year-over-year. In the year 2023, Maravai LifeSciences Holdings had annual revenue of $288.95M, a decrease of -67.28%.
Revenue (ttm)
$274.10M
Revenue Growth
-61.81%
P/S Ratio
5.49
Revenue / Employee
$421,691
Employees
650
Market Cap
1.50B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 288.95M | -594.06M | -67.28% |
Dec 31, 2022 | 883.00M | 83.76M | 10.48% |
Dec 31, 2021 | 799.24M | 515.14M | 181.33% |
Dec 31, 2020 | 284.10M | 140.96M | 98.48% |
Dec 31, 2019 | 143.14M | 19.31M | 15.59% |
Dec 31, 2018 | 123.83M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
National HealthCare | 1.17B |
Pacira BioSciences | 681.75M |
Alphatec Holdings | 511.63M |
Arcus Biosciences | 237.00M |
Dynavax Technologies | 236.15M |
Avadel Pharmaceuticals | 55.14M |
Tarsus Pharmaceuticals | 42.56M |
Spyre Therapeutics | 688.00K |
MRVI News
- 5 days ago - TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center - Business Wire
- 9 days ago - Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule - GlobeNewsWire
- 10 days ago - Maravai LifeSciences Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 18 days ago - TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology - Business Wire
- 4 weeks ago - TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production - Business Wire
- 5 weeks ago - Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024 - GlobeNewsWire
- 2 months ago - Maravai LifeSciences Announces March 2024 Investor Conference Schedule - GlobeNewsWire
- 3 months ago - Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire